4.7 Review

The Prognostic Value of Pentraxin-3 in COVID-19 Patients: A Systematic Review and Meta-Analysis of Mortality Incidence

期刊

出版社

MDPI
DOI: 10.3390/ijms24043537

关键词

Pentraxin-3 (PTX3); COVID-19; SARS-CoV-2; mortality; immunopathology

向作者/读者索取更多资源

Over the past three years, the global spread of COVID-19 has presented humanity with one of the most serious health emergencies. Identifying reliable biomarkers for COVID-19 mortality is a key objective, and pentraxin 3 (PTX3), a protein associated with innate immunity, appears to be linked to worse outcomes in the disease. This systematic review and meta-analysis evaluated the prognostic potential of PTX3 in COVID-19 and found increased levels of PTX3 in severe cases, particularly among ICU patients, suggesting it could be a reliable marker for poor outcomes and stratification of hospitalized patients.
Over the last three years, humanity has been facing one of the most serious health emergencies due to the global spread of Coronavirus disease (COVID-19). In this scenario, the research of reliable biomarkers of mortality from COVID-19 represents a primary objective. Pentraxin 3 (PTX3), a highly conserved protein of innate immunity, seems to be associated with a worse outcome of the disease. Based on the above, this systematic review and meta-analysis evaluated the prognostic potential of PTX3 in COVID-19 disease. We included 12 clinical studies evaluating PTX3 in COVID-19 patients. From our research, we found increased PTX3 levels compared to healthy subjects, and notably, PTX3 was even more augmented in severe COVID-19 rather than non-severe cases. Moreover, we performed a meta-analysis to establish if there were differences between ICU and non-ICU COVID-19 patients in PTX3-related death. We combined 5 studies for a total of 543 ICU vs. 515 non-ICU patients. We found high significative PTX3-related death in ICU COVID-19 hospitalized individuals (184 out of 543) compared to non-ICU (37 out of 515), with an overall effect OR: 11.30 [2.00, 63.73]; p = 0.006. In conclusion, we probed PTX3 as a reliable marker of poor outcomes after COVID-19 infection as well as a predictor of hospitalized patients' stratification.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据